IN THE CLAIMS:

The following listing of the claims herein replaces all previous listings of the claims.

1. (Currently Amended): A compound having Formula (I)



(I)

wherein

X is oxy, methylene or thio;

Y is CH or N;

Z is H, (C_1-C_4)alkyl, (C_1-C_4)alkyloxy, trifluoromethyl or halo;

R^1 is (C_1-C_3)alkoxymethyl, (C_3-C_5)cycloalkoxymethyl, carboxy, (C_1-C_3)alkoxycarbonyl, (C_3-C_5)cycloalkoxycarbonyl,

1,1-aminoiminomethyl, 1,1-(mono-N- or di-N,N-(C_1-C_4)alkylamino)iminomethyl, 1,1-(mono-N- or di-N,N-(C_3-C_5)cycloalkylamino)iminomethyl, carbamoyl, mono-N- or

di-N,N-(C_1-C_4)alkylaminocarbonyl, mono-N- or di-N,N-(C_3-C_5)cycloalkylaminocarbonyl, or N-(C_1-C_4)alkyl-N-(C_3-C_5)cycloalkylaminocarbonyl;

R^2 is H, (C_1-C_3)alkyl or (C_3-C_5)cycloalkyl;

A is $-(CH_2)_n-$ where n is and integer from 1 to 4, or $-(C_mH_{2m-2})-$ where m is an integer from 3 to 6; and

B is hydrogen, substituted or unsubstituted heteroaryl, substituted aryl, -CH(aryl)$_2$, or



where R^{B1} is (C_1-C_4)alkyl, halo, hydroxy, thio, amino, (C_1-C_6)alkyloxy, (C_1-C_6)alkylthio, (C_1-C_6)alkylamino or -D-G,

R^{B2} is hydrogen, ~~and is~~ (C_1-C_4)alkyl, halo, hydroxy, thio, amino, (C_1-C_6)alkyloxy, (C_1-C_6)alkylthio, (C_1-C_6)alkylamino or -D-G,

R^{B3} is (C_1-C_4)alkyl, halo, hydroxy, thio, amino, is (C_1-C_6)alkyloxy, (C_1-C_6)alkylthio, (C_1-C_6)alkylamino or -D-G,

R^{B4} is (C_1-C_4)alkyl, halo, hydroxy, thio, amino, (C_1-C_6)alkyloxy, (C_1-C_6)alkylthio, (C_1-C_6)alkylamino or -D-G,

R^{B5} is (C_1-C_4)alkyl, halo, hydroxy, thio, amino, (C_1-C_6)alkyloxy, (C_1-C_6)alkylthio, (C_1-C_6)alkylamino or -D-G,

D is oxy, thio, NH, (C_1-C_6)alkyloxy, (C_1-C_6)alkylthio or (C_1-C_6)alkylamino and

G is a partially saturated, fully saturated or fully unsaturated five to eight membered ring optionally having one to three heteroatoms selected independently from oxygen, sulfur and nitrogen, or a bicyclic ring consisting of two fused partially saturated, fully saturated or fully unsaturated three to six membered rings, taken independently, optionally having one to four heteroatoms selected independently from nitrogen, sulfur and oxygen, wherein G is optionally mono-, di- or tri-substituted independently with halo, $(C_1\text{-}C_3)$alkyl, trifluoromethyl, trifluoromethoxy, nitro, cyano, $(C_3\text{-}C_5)$cycloalkyl, hydroxy or $(C_1\text{-}C_3)$alkoxy, or

G is cyano, $(C_1\text{-}C_4)$alkoxycarbonyl, $(C_3\text{-}C_5)$cycloalkoxycarbonyl, $C(O)NR^4R^5$, $C(S)NR^4R^5$, $C(NH)NR^4R^5$, $C(N(C_1\text{-}C_3)\text{alkyl})NR^4R^5$ or $C(N(C_3\text{-}C_{10})\text{cycloalkyl})NR^4R^5$, where

R^4 is H, $(C_1\text{-}C_{10})$alkyl, hydroxy, $(C_1\text{-}C_{10})$alkoxy, $(C_3\text{-}C_{10})$cycloalkoxy or a partially saturated, fully saturated or fully unsaturated five to eight membered ring, optionally linked through $(C_1\text{-}C_3)$alkyl, optionally having one to three heteroatoms selected independently from oxygen, sulfur and nitrogen, or, a bicyclic ring or a bicyclic ring with optional $(C_1\text{-}C_3)$ bridge optionally linked through $(C_1\text{-}C_3)$alkyl, said bicyclic ring or bridged bicyclic ring optionally having one to four heteroatoms selected independently from nitrogen, sulfur and oxygen wherein said $(C_1\text{-}C_{10})$alkyl, $(C_1\text{-}C_{10})$alkoxy, $(C_3\text{-}C_{10})$cycloalkoxy or R^4 ring(s) is optionally mono-, di- or tri-substituted independently with halo, $(C_1\text{-}C_3)$alkyl, trifluoromethyl, nitro, cyano, $(C_3\text{-}C_5)$cycloalkyl, hydroxy or $(C_1\text{-}C_3)$alkoxy, and

R^5 is H, $(C_1\text{-}C_{10})$alkyl or $(C_1\text{-}C_{10})$cycloalkyl; or R^4 and R^5 taken together with the nitrogen to which they are attached form a fully saturated or partially unsaturated four to nine membered ring, said ring optionally bridged, optionally having one to three additional heteroatoms selected independently from oxygen, sulfur and nitrogen, said ring optionally mono-

or di-substituted independently with oxo, hydroxy, (C_1-C_6)alkoxy, (C_1-C_8)alkyl, amino, mono-N- or di-N,N-(C_1-C_4)alkylaminocarbonyl, mono-N- or di-N,N-(C_3-C_5)cycloalkyl- aminocarbonyl, N-(C_1-C_4)alkyl-N-(C_3-C_5)cycloalkylaminocarbonyl, mono-N- or di-N,N-(C_1-C_4)alkylamino, mono-N- or di-N,N-(C_3-C_5)cycloalkylamino, N-(C_1-C_4)alkyl-N-(C_3-C_5)cycloalkylamino, formylamino, (C_1-C_4)alkylcarbonylamino, (C_3-C_5)cycloalkylcarbonylamino, (C_1-C_4)alkoxycarbonylamino, N-(C_1-C_4)alkoxycarbonyl-N-(C_1-C_4)alkylamino, (C_1-C_4)sulfamoyl, (C_1-C_4)alkylsulfonylamino, (C_3-C_5)cycloalkylsulfonylamino or a partially saturated, fully saturated or fully unsaturated five to eight membered ring, optionally linked through (C_1-C_3)alkyl, optionally having one to three heteroatoms selected independently from oxygen, sulfur and nitrogen, or a bicyclic ring consisting of two fused partially saturated, fully saturated or fully unsaturated three to six membered rings, taken independently, optionally linked through (C_1-C_3)alkyl, optionally having one to four heteroatoms selected independently from nitrogen, sulfur and oxygen, optionally mono- or di-substituted with halo, trifluoromethyl, trifluoromethoxy, (C_1-C_3)alkyl or (C_1-C_3)alkoxy;

a prodrug thereof or a pharmaceutical acceptable salt, hydrate or solvate of said compound or said prodrug;

provided that A is not -$(CH_2)_1$-, when R^{B1} is –D-G, R^{B4} is halo, trifluoromethyl, cyano, (C_1-C_3) alkyl, (C_1-C_3) alkyloxy, ethenyl or ethynyl, and R^{B2}, R^{B3} and R^{B5} are hydrogen.

2. (Previously Presented): The compound of Claim 1 wherein

X is oxy;

Y is N;

Z is H or Cl;

R^1 is $(C_1$-$C_6)$alkylcarbamoyl;

R^2 is H;

A is $-(CH_2)_n$-, where n is 1 or 2, or cyclopropyl; and

B is substituted or unsubstituted heteroaryl, naphthyl, -CH(aryl)$_2$, or



where R^{B1} is $(C_1$-$C_4)$alkyl, halo, hydroxy, thio, amino, $(C_1$-$C_6)$alkyloxy, $(C_1$-$C_6)$alkylthio, $(C_1$-$C_6)$alkylamino or -D-G,

R^{B2} is $(C_1$-$C_4)$alkyl, halo, hydroxy, thio, amino, $(C_1$-$C_6)$alkyloxy, $(C_1$-$C_6)$alkylthio, $(C_1$-$C_6)$alkylamino or -D-G,

R^{B3} is $(C_1$-$C_4)$alkyl, halo, hydroxy, thio, amino, $(C_1$-$C_6)$alkyloxy, $(C_1$-$C_6)$alkylthio, $(C_1$-$C_6)$alkylamino or -D-G,

R^{B4} is $(C_1$-$C_4)$alkyl, halo, hydroxy, thio, amino, $(C_1$-$C_6)$alkyloxy, $(C_1$-$C_6)$alkylthio, $(C_1$-$C_6)$alkylamino or -D-G,

R^{B5} is $(C_1$-$C_4)$alkyl, halo, hydroxy, thio, amino, $(C_1$-$C_6)$alkyloxy, $(C_1$-$C_6)$alkylthio, $(C_1$-$C_6)$alkylamino or -D-G,

D is oxy, thio, $(C_1$-$C_6)$alkyloxy or $(C_1$-$C_6)$alkylthio, and

G is phenyl, pyridyl, pyrimidinyl, pyrazinyl, thiazolyl, oxazolyl, isoxazolyl, pyridinazinyl, tetrazolyl, isothiazolyl, thiophenyl, furanyl, 1,2,4-oxadiazolyl, 1,2,4-thiadiazolyl, pyrazolyl, pyrrolyl, indolyl, naphthalenyl, quinolinyl, isoquinolinyl, benzo[b]furanyl, benzo[b]thiophenyl, benzothiazolyl, tetrahydrofuranyl, pyrrolidinyl, piperidinyl, tetrahydropyranyl, morpholinyl wherein said G is optionally mono-, di- or tri-substituted independently with halo, $(C_1$-$C_3)$alkyl or $(C_1$-$C_3)$alkoxy;

a prodrug thereof, or a pharmaceutically acceptable salt, hydrate or solvate of said compound or said prodrug.

3. (Original): The compound of Claim 2 wherein B is a substituted or unsubstituted pyridyl, indolyl or thiazolyl; a prodrug thereof, or a pharmaceutically acceptable salt, solvate, or hydrate of said compound or said prodrug.

4. (Original): The compound of Claim 3 wherein said substituted pyridyl, indolyl or thiazolyl is substituted with at least one substituent selected from the group consisting of $(C_1$-$C_4)$alkyl, halo, hydroxy, thio, amino, $(C_1$-$C_6)$alkyloxy, $(C_1$-$C_6)$alkylthio, $(C_1$-$C_6)$alkylamino and –D-G, where D is oxy, thio, $(C_1$-$C_6)$alkyloxy or $(C_1$-$C_6)$alkylthio, and G is phenyl, pyridyl, pyrimidinyl, pyrazinyl, thiazolyl, oxazolyl, isoxazolyl, pyridinazinyl, tetrazolyl, isothiazolyl, thiophenyl, furanyl, 1,2,4-oxadiazolyl, 1,2,4-thiadiazolyl, pyrazolyl, pyrrolyl, indolyl, naphthalenyl, quinolinyl, isoquinolinyl, benzo[b]furanyl, benzo[b]thiophenyl, benzothiazolyl, tetrahydrofuranyl, pyrrolidinyl, piperidinyl, tetrahydropyranyl, morpholinyl wherein said G is optionally mono-, di- or tri-substituted independently with halo, $(C_1$-$C_3)$alkyl or $(C_1$-$C_3)$alkoxy; a

prodrug thereof, or a pharmaceutically acceptable salt, solvate, or hydrate of said compound or said prodrug.

5. (Previously Presented): The compound of Claim 2 wherein B is



where R^{B1} is (C_1-C_4)alkyl, halo, hydroxy, (C_1-C_6)alkyloxy or -D-G,

R^{B2} is hydrogen, (C_1-C_4)alkyl, halo, hydroxy, (C_1-C_6)alkyloxy or -D-G,

R^{B3} is hydrogen, (C_1-C_4)alkyl, halo, hydroxy, (C_1-C_6)alkyloxy or -D-G,

R^{B4} is hydrogen, (C_1-C_4)alkyl, halo, hydroxy, (C_1-C_6)alkyloxy or -D-G,

R^{B5} is hydrogen, (C_1-C_4)alkyl, halo, hydroxy, (C_1-C_6)alkyloxy or -D-G,

D is (C_1-C_6)alkoxy and

G is phenyl, pyridyl, thiazolyl, oxazolyl, isoxazolyl, isothiazolyl, furanyl, 1,2,4-oxadiazolyl, 1,2,4-thiadiazolyl, pyrazolyl, pyrrolyl, or morpholinyl wherein said G is optionally mono-, di- or tri-substituted independently with halo, (C_1-C_3)alkyl, trifluoromethoxy or (C_1-C_3)alkoxy;

a prodrug thereof, or a pharmaceutically acceptable salt, hydrate or solvate of said compound or said prodrug.

6. (Original): A compound selected from the group consisting of

(2S,3S,4R,5R) 3-amino-5-{6-[2-(2,5-dimethoxy-phenyl)-ethylamino]-purin-9-yl}-4-hydroxy-tetrahydro-furan-2-carboxylic acid methylamide,

(2S,3S,4R,5R) 3-amino-4-hydroxy-5-[6-(3-methoxy-benzylamino)-purin-9-yl]-tetrahydro-furan-2-carboxylic acid methylamide,

(2S,3S,4R,5R) 3-amino-5-[6-(4-benzyloxy-benzylamino)-purin-9-yl]-4-hydroxy-tetrahydro-furan-2-carboxylic acid methylamide,

(2S,3S,4R,5R) 3-amino-4-hydroxy-5-[6-(2-hydroxy-5-methoxy-benzylamino)-purin-9-yl]-tetrahydro-furan-2-carboxylic acid methylamide,

(2S,3S,4R,5R) 3-amino-5-[6-(3-butoxy-benzylamino)-purin-9-yl]-4-hydroxy-tetrahydro-furan-2-carboxylic acid methylamide,

(2S,3S,4R,5R) 3-amino-5-[6-(2,5-dimethyl-benzylamino)-purin-9-yl]-4-hydroxy-tetrahydro-furan-2-carboxylic acid methylamide,

(2S,3S,4R,5R) 3-amino-5-[6-(2,5-dichloro-benzylamino)-purin-9-yl]-4-hydroxy-tetrahydro-furan-2-carboxylic acid methylamide,

(2S,3S,4R,5R) 3-amino-4-hydroxy-5-{6-[3-(2-morpholin-4-yl-ethoxy)-benzylamino]-purin-9-yl}-tetrahydro-furan-2-carboxylic acid methylamide,

(2S,3S,4R,5R) 3-amino-4-hydroxy-5-{6-[3-(3-methyl-isoxazol-5-ylmethoxy)-benzylamino]-purin-9-yl}-tetrahydro-furan-2-carboxylic acid methylamide,

(2S,3S,4R,5R) 3-amino-4-hydroxy-5-[6-(2-methoxy-5-methyl-benzylamino)-purin-9-yl-tetrahydro-furan-2-carboxylic acid methylamide,

(2S,3S,4R,5R) 3-amino-5-[6-(2,5-diethyl-benzylamino)-purin-9-yl]-4-hydroxy-tetrahydro-furan-2-carboxylic acid methylamide,

(2S,3S,4R,5R) 3-amino-5-{6-[2-(1-ethyl-propoxy)-5-methoxy-benzylamino]-purin-9-yl}-4-hydroxy-tetrahydro-furan-2-carboxylic acid methylamide,

(2S,3S,4R,5R) 3-amino-5-[6-(3-cyclopentyloxy-benzylamino)-purin-9-yl]-4-hydroxy-tetrahydro-furan-2-carboxylic acid methylamide.

(2S,3S,4R,5R) 3-amino-5-[6-(2-cyclopentyloxy-benzylamino)-purin-9-yl]-4-hydroxy-tetrahydro-furan-2-carboxylic acid methylamide,

(2S,3S,4R,5R) 3-amino-5-[6-(5-chloro-2-isopropoxy-benzylamino)-purin-9-yl]-4-hydroxy-tetrahydro-furan-2-carboxylic acid methylamide,

(2S,3S,4R,5R) 3-amino-5-[6-(2-benzyloxy-benzylamino)-purin-9-yl]-4-hydroxy-tetrahydro-furan-2-carboxylic acid methylamide,

(2S,3S,4R,5R) 3-amino-5-{6-[2-(4-fluoro-phenyl)-ethylamino]-purin-9-yl}-4-hydroxy-tetrahydro-furan-2-carboxylic acid methylamide.

(2S,3S,4R,5R) 3-amino-5-{6-[2-(4-benzyloxy-3,5-dimethoxy-phenyl)-ethylamino]-purin-9-yl}-4-hydroxy-tetrahydro-furan-2-carboxylic acid methylamide,

(2S,3S,4R,5R) 3-amino-4-hydroxy-5-(6-methylamino-purin-9-yl)-tetrahydro-furan-2-carboxylic acid methylamide,

(2S,3S,4R,5R) 3-amino-5-{6-[2-(4-fluoro-3-methoxy-phenyl)-ethylamino]-purin-9-yl}-4-hydroxy-tetrahydro-furan-2-carboxylic acid methylamide,

(2S,3S,4R,5R) 3-amino-5-{6-[(3-benzyloxy-6-methyl-pyridin-2-ylmethyl)-amino]-purin-9-yl}-4-hydroxy-tetrahydro-furan-2-carboxylic acid methylamide,

(2S,3S,4R,5R) 3-amino-5-[6-(2,2-diphenyl-ethylamino)-purin-9-yl]-4-hydroxy-tetrahydro-furan-2-carboxylic acid methylamide,

(2S,3S,4R,5R) 3-amino-5-[2-chloro-6-(2,5-dimethoxy-benzylamino)-purin-9-yl]-4-hydroxy-tetrahydro-furan-2-carboxylic acid methylamide,

(2S,3S,4R,5R) 3-amino-5-{6-[2-(3-benzyloxy-4-methoxy-phenyl)-ethylamino]-purin-9-yl}-4-hydroxy-tetrahydro-furan-2-carboxylic acid methylamide,

(2S,3S,4R,5R) 3-amino-4-hydroxy-5-[6-(2-pyridin-3-yl-ethylamino)-purin-9-yl]-tetrahydro-furan-2-carboxylic acid methylamide,

(2S,3S,4R,5R) 3-amino-5-[6-(2,5-dimethoxy-benzylamino)-purin-9-yl]-4-hydroxy-tetrahydro-furan-2-carboxylic acid methylamide,

(2S,3S,4R,5R) 3-amino-4-hydroxy-5-(6-phenethylamino-purin-9-yl)-tetrahydro-furan-2-carboxylic acid methylamide,

(2S,3S,4R,5R) 3-amino-5-(2-chloro-6-methylamino-purin-9-yl)-4-hydroxy-tetrahydro-furan-2-carboxylic acid methylamide,

(2S,3S,4R,5R) 3-amino-4-hydroxy-5-[6-(2-phenyl-cyclopropylamino)-purin-9-yl]-tetrahydro-furan-2-carboxylic acid methylamide,

(2S,3S,4R,5R) 3-amino-5-[2-chloro-6-(2,5-dichloro-benzylamino)-purin-9-yl]-4-hydroxy-tetrahydro-furan-2-carboxylic acid methylamide,

(2S,3S,4R,5R) 3-amino-4-hydroxy-5-{6-[2-(2-morpholin-4-yl-thiazol-5-yl)-ethylamino]-purin-9-yl}-tetrahydro-furan-2-carboxylic acid methylamide,

(2S,3S,4R,5R) 3-amino-4-hydroxy-5-[6-(2-naphthalen-1-yl-ethylamino)-purin-9-yl]-tetrahydro-furan-2-carboxylic acid methylamide,

(2S,3S,4R,5R) 3-amino-5-{6-[(5-fluoro-1H-indol-3-ylmethyl)-amino]-purin-9-yl}-4-hydroxy-tetrahydro-furan-2-carboxylic acid methylamide,

(2S,3S,4R,5R) 3-amino-5-{6-[2-(4-benzyloxy-3-methoxy-phenyl)-ethylamino]-purin-9-yl}-4-hydroxy-tetrahydro-furan-2-carboxylic acid methylamide,

(2S,3S,4R,5R) 3-amino-4-hydroxy-5-[6-(2-pyridin-2-yl-ethylamino)-purin-9-yl]-tetrahydro-furan-2-carboxylic acid methylamide, and

(2S,3S,4R,5R) 3-amino-4-hydroxy-5-[6-(2-phenyl-cyclopropylamino)-purin-9-yl]-tetrahydro-furan-2-carboxylic acid methylamide;

a prodrug thereof, or a pharmaceutically acceptable salt, solvate, or hydrate of said compound or said prodrug.

7. (Cancelled)

8. (Original): The method of Claim 7 wherein the tissue is cardiac, brain, liver, kidney, lung, gut, skeletal muscle, spleen, pancreas, nerve, spinal cord, retina tissue, the vasculature, or intestinal tissue.

9. (Original): The method of Claim 7 wherein said effective amount of said compound, prodrug thereof, or pharmaceutically acceptable salt, hydrate or solvate of said compound or said prodrug is about 0.01 mg/kg/day to about 50 mg/kg/day.

10. (Original): The method of Claim 9 wherein said mammal is a human.

11. (Original): The method of Claim 10 wherein the compound is administered prior to, during and after cardiac surgery.

12. – 23. (Cancelled)

24. (Previously Presented): A compound having Formula (I)



(I)

wherein

X is oxy, methylene or thio;

Y is CH or N;

Z is H, (C_1-C_4)alkyl, (C_1-C_4)alkyloxy, trifluoromethyl or halo;

R^1 is (C_1-C_3)alkoxymethyl, (C_3-C_5)cycloalkoxymethyl, carboxy, (C_1-C_3)alkoxycarbonyl, (C_3-C_5)cycloalkoxycarbonyl,

1,1-aminoiminomethyl, 1,1-(mono-N- or di-N,N-(C_1-C_4)alkylamino)iminomethyl, 1,1-(mono-N- or di-N,N-(C_3-C_5)cycloalkylamino)iminomethyl, carbamoyl, mono-N- or

di-N,N-(C_1-C_4)alkylaminocarbonyl, mono-N- or di-N,N-(C_3-C_5)cycloalkylaminocarbonyl, or N-(C_1-C_4)alkyl-N-(C_3-C_5)cycloalkylaminocarbonyl;

R^2 is H, (C_1-C_3)alkyl or (C_3-C_5)cycloalkyl;

A is $-(CH_2)_n-$ where n is and integer from 1 to 4, or $-(C_mH_{2m-2})-$ where m is an integer from 3 to 6; and

B is hydrogen, substituted or unsubstituted heteroaryl, substituted aryl, -CH(aryl)$_2$, or



where R^{B1}, is hydrogen, (C_1-C_4)alkyl, halo, hydroxy, thio, amino, (C_1-C_6)alkyloxy, (C_1-C_6)alkylthio, (C_1-C_6)alkylamino or -D-G,

R^{B2} is (C_1-C_4)alkyl, halo, hydroxy, thio, amino, (C_1-C_6)alkyloxy, (C_1-C_6)alkylthio, (C_1-C_6)alkylamino or -D-G,

R^{B3} is hydrogen, (C_1-C_4)alkyl, halo, hydroxy, thio, amino, is (C_1-C_6)alkyloxy, (C_1-C_6)alkylthio, (C_1-C_6)alkylamino or -D-G,

R^{B4} is hydrogen, (C_1-C_4)alkyl, halo, hydroxy, thio, amino, (C_1-C_6)alkyloxy, (C_1-C_6)alkylthio, (C_1-C_6)alkylamino or -D-G,

R^{B5} is hydrogen, (C_1-C_4)alkyl, halo, hydroxy, thio, amino, (C_1-C_6)alkyloxy, (C_1-C_6)alkylthio, (C_1-C_6)alkylamino or -D-G,

D is oxy, thio, NH, (C_1-C_6)alkyloxy, (C_1-C_6)alkylthio or (C_1-C_6)alkylamino and

G is a partially saturated, fully saturated or fully unsaturated five to eight membered ring optionally having one to three heteroatoms selected independently from oxygen, sulfur and nitrogen, or a bicyclic ring consisting of two fused partially saturated, fully saturated or fully unsaturated three to six membered rings, taken independently, optionally having one to four heteroatoms selected independently from nitrogen, sulfur and oxygen, wherein G is optionally mono-, di- or tri-substituted independently with halo, $(C_1\text{-}C_3)$alkyl, trifluoromethyl, trifluoromethoxy, nitro, cyano, $(C_3\text{-}C_5)$cycloalkyl, hydroxy or $(C_1\text{-}C_3)$alkoxy, or

G is cyano, $(C_1\text{-}C_4)$alkoxycarbonyl, $(C_3\text{-}C_5)$cycloalkoxycarbonyl, $C(O)NR^4R^5$, $C(S)NR^4R^5$, $C(NH)NR^4R^5$, $C(N(C_1\text{-}C_3)\text{alkyl})NR^4R^5$ or $C(N(C_3\text{-}C_{10})\text{cycloalkyl})NR^4R^5$, where

R^4 is H, $(C_1\text{-}C_{10})$alkyl, hydroxy, $(C_1\text{-}C_{10})$alkoxy, $(C_3\text{-}C_{10})$cycloalkoxy or a partially saturated, fully saturated or fully unsaturated five to eight membered ring, optionally linked through $(C_1\text{-}C_3)$alkyl, optionally having one to three heteroatoms selected independently from oxygen, sulfur and nitrogen, or, a bicyclic ring or a bicyclic ring with optional $(C_1\text{-}C_3)$ bridge optionally linked through $(C_1\text{-}C_3)$alkyl, said bicyclic ring or bridged bicyclic ring optionally having one to four heteroatoms selected independently from nitrogen, sulfur and oxygen wherein said $(C_1\text{-}C_{10})$alkyl, $(C_1\text{-}C_{10})$alkoxy, $(C_3\text{-}C_{10})$cycloalkoxy or R^4 ring(s) is optionally mono-, di- or tri-substituted independently with halo, $(C_1\text{-}C_3)$alkyl, trifluoromethyl, nitro, cyano, $(C_3\text{-}C_5)$cycloalkyl, hydroxy or $(C_1\text{-}C_3)$alkoxy, and

R^5 is H, $(C_1\text{-}C_{10})$alkyl or $(C_1\text{-}C_{10})$cycloalkyl; or R^4 and R^5 taken together with the nitrogen to which they are attached form a fully saturated or partially unsaturated four to nine membered ring, said ring optionally bridged, optionally having one to three additional heteroatoms selected independently from oxygen, sulfur and nitrogen, said ring optionally mono-

or di-substituted independently with oxo, hydroxy, (C_1-C_6)alkoxy, (C_1-C_8)alkyl, amino, mono-N- or di-N,N-(C_1-C_4)alkylaminocarbonyl, mono-N- or di-N,N-(C_3-C_5)cycloalkyl- aminocarbonyl, N-(C_1-C_4)alkyl-N-(C_3-C_5)cycloalkylaminocarbonyl, mono-N- or di-N,N-(C_1-C_4)alkylamino, mono-N- or di-N,N-(C_3-C_5)cycloalkylamino, N-(C_1-C_4)alkyl-N-(C_3-C_5)cycloalkylamino, formylamino, (C_1-C_4)alkylcarbonylamino, (C_3-C_5)cycloalkylcarbonylamino, (C_1-C_4)alkoxycarbonylamino, N-(C_1-C_4)alkoxycarbonyl-N-(C_1-C_4)alkylamino, (C_1-C_4)sulfamoyl, (C_1-C_4)alkylsulfonylamino, (C_3-C_5)cycloalkylsulfonylamino or a partially saturated, fully saturated or fully unsaturated five to eight membered ring, optionally linked through (C_1-C_3)alkyl, optionally having one to three heteroatoms selected independently from oxygen, sulfur and nitrogen, or a bicyclic ring consisting of two fused partially saturated, fully saturated or fully unsaturated three to six membered rings, taken independently, optionally linked through (C_1-C_3)alkyl, optionally having one to four heteroatoms selected independently from nitrogen, sulfur and oxygen, optionally mono- or di-substituted with halo, trifluoromethyl, trifluoromethoxy, (C_1-C_3)alkyl or (C_1-C_3)alkoxy;

a prodrug thereof or a pharmaceutical acceptable salt, hydrate or solvate of said compound or said prodrug;

provided that A is not -$(CH_2)_1$-, when R^{B1} is –D-G, R^{B4} is halo, trifluoromethyl, cyano, (C_1-C_3) alkyl, (C_1-C_3) alkyloxy, ethenyl or ethynyl, and R^{B2}, R^{B3} and R^{B5} are hydrogen.

25. (Previously Presented): The compound of Claim 24 wherein

X is oxy;

Y is N;

Z is H or Cl;

R^1 is $(C_1\text{-}C_6)$alkylcarbamoyl;

R^2 is H;

A is $-(CH_2)_n-$, where n is 1 or 2, or cyclopropyl; and

B is substituted or unsubstituted heteroaryl, naphthyl, $-CH(aryl)_2$, or



where R^{B1} is hydrogen, $(C_1\text{-}C_4)$alkyl, halo, hydroxy, thio, amino, $(C_1\text{-}C_6)$alkyloxy, $(C_1\text{-}C_6)$alkylthio, $(C_1\text{-}C_6)$alkylamino or -D-G,

R^{B2} is $(C_1\text{-}C_4)$alkyl, halo, hydroxy, thio, amino, $(C_1\text{-}C_6)$alkyloxy, $(C_1\text{-}C_6)$alkylthio, $(C_1\text{-}C_6)$alkylamino or and -D-G,

R^{B3} is hydrogen, $(C_1\text{-}C_4)$alkyl, halo, hydroxy, thio, amino, $(C_1\text{-}C_6)$alkyloxy, $(C_1\text{-}C_6)$alkylthio, $(C_1\text{-}C_6)$alkylamino or and -D-G,

R^{B4} is hydrogen, $(C_1\text{-}C_4)$alkyl, halo, hydroxy, thio, amino, $(C_1\text{-}C_6)$alkyloxy, $(C_1\text{-}C_6)$alkylthio, $(C_1\text{-}C_6)$alkylamino or and -D-G,

R^{B5} is hydrogen, $(C_1\text{-}C_4)$alkyl, halo, hydroxy, thio, amino, $(C_1\text{-}C_6)$alkyloxy, $(C_1\text{-}C_6)$alkylthio, $(C_1\text{-}C_6)$alkylamino or and -D-G,

D is oxy, thio, $(C_1\text{-}C_6)$alkyloxy or $(C_1\text{-}C_6)$alkylthio, and

G is phenyl, pyridyl, pyrimidinyl, pyrazinyl, thiazolyl, oxazolyl, isoxazolyl, pyridinazinyl, tetrazolyl, isothiazolyl, thiophenyl, furanyl, 1,2,4-oxadiazolyl, 1,2,4-thiadiazolyl, pyrazolyl, pyrrolyl, indolyl, naphthalenyl, quinolinyl, isoquinolinyl, benzo[b]furanyl, benzo[b]thiophenyl, benzothiazolyl, tetrahydrofuranyl, pyrrolidinyl, piperidinyl, tetrahydropyranyl, morpholinyl wherein said G is optionally mono-, di- or tri-substituted independently with halo, $(C_1\text{-}C_3)$alkyl or $(C_1\text{-}C_3)$alkoxy;

a prodrug thereof, or a pharmaceutically acceptable salt, hydrate or solvate of said compound or said prodrug.

26. (Previously Presented): The compound of Claim 25 wherein B is



where R^{B1} is $(C_1\text{-}C_4)$alkyl, halo, hydroxy, $(C_1\text{-}C_6)$alkyloxy or -D-G,

R^{B2} is hydrogen, $(C_1\text{-}C_4)$alkyl, halo, hydroxy, $(C_1\text{-}C_6)$alkyloxy or -D-G,

R^{B3} is hydrogen, $(C_1\text{-}C_4)$alkyl, halo, hydroxy, $(C_1\text{-}C_6)$alkyloxy or -D-G,

R^{B4} is hydrogen, $(C_1\text{-}C_4)$alkyl, halo, hydroxy, $(C_1\text{-}C_6)$alkyloxy or -D-G,

R^{B5} is hydrogen, $(C_1\text{-}C_4)$alkyl, halo, hydroxy, $(C_1\text{-}C_6)$alkyloxy or -D-G,

D is $(C_1\text{-}C_6)$alkoxy and

G is phenyl, pyridyl, thiazolyl, oxazolyl, isoxazolyl, isothiazolyl, furanyl, 1,2,4-oxadiazolyl, 1,2,4-thiadiazolyl, pyrazolyl, pyrrolyl, or morpholinyl wherein said G is optionally mono-, di- or tri-substituted independently with halo, (C_1-C_3)alkyl, trifluoromethoxy or (C_1-C_3)alkoxy;

a prodrug thereof, or a pharmaceutically acceptable salt, hydrate or solvate of said compound or said prodrug.

27. (Previously Presented): A compound having Formula (I)



(I)

wherein

X is oxy, methylene or thio;

Y is CH or N;

Z is H, (C_1-C_4)alkyl, (C_1-C_4)alkyloxy, trifluoromethyl or halo;

R^1 is (C_1-C_3)alkoxymethyl, (C_3-C_5)cycloalkoxymethyl, carboxy, (C_1-C_3)alkoxycarbonyl, (C_3-C_5)cycloalkoxycarbonyl,

1,1-aminoiminomethyl, 1,1-(mono-N- or di-N,N-(C_1-C_4)alkylamino)iminomethyl, 1,1-(mono-N- or di-N,N-(C_3-C_5)cycloalkylamino)iminomethyl, carbamoyl, mono-N- or di-N,N-(C_1-C_4)alkylaminocarbonyl, mono-N- or di-N,N-(C_3-C_5)cycloalkylaminocarbonyl, or N-(C_1-C_4)alkyl-N-(C_3-C_5)cycloalkylaminocarbonyl;

R^2 is H, (C_1-C_3)alkyl or (C_3-C_5)cycloalkyl;

A is $-(CH_2)_n-$ where n is and integer from 1 to 4, or $-(C_mH_{2m-2})-$ where m is an integer from 3 to 6; and

B is hydrogen, substituted or unsubstituted heteroaryl, substituted aryl, -CH(aryl)$_2$, or



where R^{B1} is hydrogen, (C_1-C_4)alkyl, halo, hydroxy, thio, amino, (C_1-C_6)alkyloxy, (C_1-C_6)alkylthio, (C_1-C_6)alkylamino or -D-G,

R^{B2} is hydrogen, (C_1-C_4)alkyl, halo, hydroxy, thio, amino, (C_1-C_6)alkyloxy, (C_1-C_6)alkylthio, (C_1-C_6)alkylamino or -D-G,

R^{B3} is (C_1-C_4)alkyl, halo, hydroxy, thio, amino, is (C_1-C_6)alkyloxy, (C_1-C_6)alkylthio, (C_1-C_6)alkylamino or -D-G,

R^{B4} is hydrogen, (C_1-C_4)alkyl, halo, hydroxy, thio, amino, (C_1-C_6)alkyloxy, (C_1-C_6)alkylthio, (C_1-C_6)alkylamino or -D-G,

R^{B5} is hydrogen, (C_1-C_4)alkyl, halo, hydroxy, thio, amino, (C_1-C_6)alkyloxy, (C_1-C_6)alkylthio, (C_1-C_6)alkylamino or -D-G,

D is oxy, thio, NH, (C_1-C_6)alkyloxy, (C_1-C_6)alkylthio or (C_1-C_6)alkylamino and

G is a partially saturated, fully saturated or fully unsaturated five to eight membered ring optionally having one to three heteroatoms selected independently from oxygen, sulfur and nitrogen, or a bicyclic ring consisting of two fused partially saturated, fully saturated or fully unsaturated three to six membered rings, taken independently, optionally having one to four heteroatoms selected independently from nitrogen, sulfur and oxygen, wherein G is optionally mono-, di- or tri-substituted independently with halo, (C_1-C_3)alkyl, trifluoromethyl, trifluoromethoxy, nitro, cyano, (C_3-C_5)cycloalkyl, hydroxy or (C_1-C_3)alkoxy, or

G is cyano, (C_1-C_4)alkoxycarbonyl, (C_3-C_5)cycloalkoxycarbonyl, $C(O)NR^4R^5$, $C(S)NR^4R^5$, $C(NH)NR^4R^5$, $C(N(C_1-C_3)alkyl)NR^4R^5$ or $C(N(C_3-C_{10})cycloalkyl)NR^4R^5$, where

R^4 is H, (C_1-C_{10})alkyl, hydroxy, (C_1-C_{10})alkoxy, (C_3-C_{10})cycloalkoxy or a partially saturated, fully saturated or fully unsaturated five to eight membered ring, optionally linked through (C_1-C_3)alkyl, optionally having one to three heteroatoms selected independently from oxygen, sulfur and nitrogen, or, a bicyclic ring or a bicyclic ring with optional (C_1-C_3) bridge optionally linked through (C_1-C_3)alkyl, said bicyclic ring or bridged bicyclic ring optionally having one to four heteroatoms selected independently from nitrogen, sulfur and oxygen wherein said (C_1-C_{10})alkyl, (C_1-C_{10})alkoxy, (C_3-C_{10})cycloalkoxy or R^4 ring(s) is optionally

mono-, di- or tri-substituted independently with halo, (C_1-C_3)alkyl, trifluoromethyl, nitro, cyano, (C_3-C_5)cycloalkyl, hydroxy or (C_1-C_3)alkoxy, and

R^5 is H, (C_1-C_{10})alkyl or (C_1-C_{10})cycloalkyl; or R^4 and R^5 taken together with the nitrogen to which they are attached form a fully saturated or partially unsaturated four to nine membered ring, said ring optionally bridged, optionally having one to three additional heteroatoms selected independently from oxygen, sulfur and nitrogen, said ring optionally mono- or di-substituted independently with oxo, hydroxy, (C_1-C_6)alkoxy, (C_1-C_8)alkyl, amino, mono-N- or di-N,N-(C_1-C_4)alkylaminocarbonyl, mono-N- or di-N,N-(C_3-C_5)cycloalkyl- aminocarbonyl, N-(C_1-C_4)alkyl-N-(C_3-C_5)cycloalkylaminocarbonyl, mono-N- or di-N,N-(C_1-C_4)alkylamino, mono-N- or di-N,N-(C_3-C_5)cycloalkylamino, N-(C_1-C_4)alkyl-N-(C_3-C_5)cycloalkylamino, formylamino, (C_1-C_4)alkylcarbonylamino, (C_3-C_5)cycloalkylcarbonylamino, (C_1-C_4)alkoxycarbonylamino, N-(C_1-C_4)alkoxycarbonyl-N-(C_1-C_4)alkylamino, (C_1-C_4)sulfamoyl, (C_1-C_4)alkylsulfonylamino, (C_3-C_5)cycloalkylsulfonylamino or a partially saturated, fully saturated or fully unsaturated five to eight membered ring, optionally linked through (C_1-C_3)alkyl, optionally having one to three heteroatoms selected independently from oxygen, sulfur and nitrogen, or a bicyclic ring consisting of two fused partially saturated, fully saturated or fully unsaturated three to six membered rings, taken independently, optionally linked through (C_1-C_3)alkyl, optionally having one to four heteroatoms selected independently from nitrogen, sulfur and oxygen, optionally mono- or di-substituted with halo, trifluoromethyl, trifluoromethoxy, (C_1-C_3)alkyl or (C_1-C_3)alkoxy;

a prodrug thereof or a pharmaceutical acceptable salt, hydrate or solvate of said compound or said prodrug;

provided that A is not -$(CH_2)_1$-, when R^{B1} is –D-G, R^{B4} is halo, trifluoromethyl, cyano, (C_1-C_3) alkyl, (C_1-C_3) alkyloxy, ethenyl or ethynyl, and R^{B2}, R^{B3} and R^{B5} are hydrogen.

28. (Previously Presented): The compound of Claim 27 wherein

X is oxy;

Y is N;

Z is H or Cl;

R^1 is (C_1-C_6)alkylcarbamoyl;

R^2 is H;

A is –$(CH_2)_n$-, where n is 1 or 2, or cyclopropyl; and

B is substituted or unsubstituted heteroaryl, naphthyl,

-CH(aryl)$_2$, or



where R^{B1} is hydrogen, (C_1-C_4)alkyl, halo, hydroxy, thio, amino, (C_1-C_6)alkyloxy, (C_1-C_6)alkylthio, (C_1-C_6)alkylamino or -D-G,

R^{B2} is hydrogen, (C_1-C_4)alkyl, halo, hydroxy, thio, amino, (C_1-C_6)alkyloxy, (C_1-C_6)alkylthio, (C_1-C_6)alkylamino or and -D-G,

R^{B3} is (C_1-C_4)alkyl, halo, hydroxy, thio, amino, (C_1-C_6)alkyloxy, (C_1-C_6)alkylthio, (C_1-C_6)alkylamino or and -D-G,

R^{B4} is hydrogen, (C_1-C_4)alkyl, halo, hydroxy, thio, amino, (C_1-C_6)alkyloxy, (C_1-C_6)alkylthio, (C_1-C_6)alkylamino or and -D-G,

R^{B5} is hydrogen, (C_1-C_4)alkyl, halo, hydroxy, thio, amino, (C_1-C_6)alkyloxy, (C_1-C_6)alkylthio, (C_1-C_6)alkylamino or and -D-G,

D is oxy, thio, (C_1-C_6)alkyloxy or (C_1-C_6)alkylthio, and

G is phenyl, pyridyl, pyrimidinyl, pyrazinyl, thiazolyl, oxazolyl, isoxazolyl, pyridinazinyl, tetrazolyl, isothiazolyl, thiophenyl, furanyl, 1,2,4-oxadiazolyl, 1,2,4-thiadiazolyl, pyrazolyl, pyrrolyl, indolyl, naphthalenyl, quinolinyl, isoquinolinyl, benzo[b]furanyl, benzo[b]thiophenyl, benzothiazolyl, tetrahydrofuranyl, pyrrolidinyl, piperidinyl, tetrahydropyranyl, morpholinyl wherein said G is optionally mono-, di- or tri-substituted independently with halo, (C_1-C_3)alkyl or (C_1-C_3)alkoxy;

a prodrug thereof, or a pharmaceutically acceptable salt, hydrate or solvate of said compound or said prodrug.

29. (Previously Presented): The compound of Claim 28 wherein B is



where R^{B1} is, R^{B2}, R^{B3}, R^{B4} and R^{B5} are each independently selected from the group consisting of hydrogen, (C_1-C_4)alkyl, halo, hydroxy, (C_1-C_6)alkyloxy or -D-G,

R^{B2} is hydrogen, (C_1-C_4)alkyl, halo, hydroxy, (C_1-C_6)alkyloxy or -D-G,

R^{B3} is (C_1-C_4)alkyl, halo, hydroxy, (C_1-C_6)alkyloxy or -D-G,

R^{B4} is hydrogen, (C_1-C_4)alkyl, halo, hydroxy, (C_1-C_6)alkyloxy or -D-G,

R^{B5} is hydrogen, (C_1-C_4)alkyl, halo, hydroxy, (C_1-C_6)alkyloxy or -D-G,

D is (C_1-C_6)alkoxy and

G is phenyl, pyridyl, thiazolyl, oxazolyl, isoxazolyl, isothiazolyl, furanyl, 1,2,4-oxadiazolyl, 1,2,4-thiadiazolyl, pyrazolyl, pyrrolyl, or morpholinyl wherein said G is optionally mono-, di- or tri-substituted independently with halo, (C_1-C_3)alkyl, trifluoromethoxy or (C_1-C_3)alkoxy;

a prodrug thereof, or a pharmaceutically acceptable salt, hydrate or solvate of said compound or said prodrug.

30. (Previously Presented): A compound having Formula (I)



(I)

wherein

X is oxy, methylene or thio;

Y is CH or N;

Z is H, (C_1-C_4)alkyl, (C_1-C_4)alkyloxy, trifluoromethyl or halo;

R^1 is (C_1-C_3)alkoxymethyl, (C_3-C_5)cycloalkoxymethyl, carboxy, (C_1-C_3)alkoxycarbonyl, (C_3-C_5)cycloalkoxycarbonyl,

1,1-aminoiminomethyl, 1,1-(mono-N- or di-N,N-(C_1-C_4)alkylamino)iminomethyl, 1,1-(mono-N- or di-N,N-(C_3-C_5)cycloalkylamino)iminomethyl, carbamoyl, mono-N- or di-N,N-(C_1-C_4)alkylaminocarbonyl, mono-N- or di-N,N-(C_3-C_5)cycloalkylaminocarbonyl, or N-(C_1-C_4)alkyl-N-(C_3-C_5)cycloalkylaminocarbonyl;

R^2 is H, (C_1-C_3)alkyl or (C_3-C_5)cycloalkyl;

A is $-(CH_2)_n-$ where n is and integer from 1 to 4, or $-(C_mH_{2m-2})-$ where m is an integer from 3 to 6; and

B is hydrogen, substituted or unsubstituted heteroaryl, substituted aryl, -CH(aryl)$_2$, or



where R^{B1} is hydrogen, (C_1-C_4)alkyl, halo, hydroxy, thio, amino, (C_1-C_6)alkyloxy, (C_1-C_6)alkylthio, (C_1-C_6)alkylamino or -D-G,

R^{B2} is hydrogen, (C_1-C_4)alkyl, halo, hydroxy, thio, amino, (C_1-C_6)alkyloxy, (C_1-C_6)alkylthio, (C_1-C_6)alkylamino or -D-G,

R^{B3} is hydrogen, (C_1-C_4)alkyl, halo, hydroxy, thio, amino, is (C_1-C_6)alkyloxy, (C_1-C_6)alkylthio, (C_1-C_6)alkylamino or -D-G,

R^{B4} is (C_1-C_4)alkyl, halo, hydroxy, thio, amino, (C_1-C_6)alkyloxy, (C_1-C_6)alkylthio, (C_1-C_6)alkylamino or -D-G,

R^{B5} is hydrogen, (C_1-C_4)alkyl, halo, hydroxy, thio, amino, (C_1-C_6)alkyloxy, (C_1-C_6)alkylthio, (C_1-C_6)alkylamino or -D-G,

D is oxy, thio, NH, (C_1-C_6)alkyloxy, (C_1-C_6)alkylthio or (C_1-C_6)alkylamino and

G is a partially saturated, fully saturated or fully unsaturated five to eight membered ring optionally having one to three heteroatoms selected independently from oxygen, sulfur and nitrogen, or a bicyclic ring consisting of two fused partially saturated, fully saturated or fully unsaturated three to six membered rings, taken independently, optionally having one to four heteroatoms selected independently from nitrogen, sulfur and oxygen, wherein G is optionally mono-, di- or tri-substituted independently with halo, (C_1-C_3)alkyl, trifluoromethyl, trifluoromethoxy, nitro, cyano, (C_3-C_5)cycloalkyl, hydroxy or (C_1-C_3)alkoxy, or

G is cyano, (C_1-C_4)alkoxycarbonyl, (C_3-C_5)cycloalkoxycarbonyl, $C(O)NR^4R^5$, $C(S)NR^4R^5$, $C(NH)NR^4R^5$, $C(N(C_1\text{-}C_3)alkyl)NR^4R^5$ or $C(N(C_3\text{-}C_{10})cycloalkyl)NR^4R^5$, where

R^4 is H, (C_1-C_{10})alkyl, hydroxy, (C_1-C_{10})alkoxy, (C_3-C_{10})cycloalkoxy or a partially saturated, fully saturated or fully unsaturated five to eight membered ring, optionally linked through (C_1-C_3)alkyl, optionally having one to three heteroatoms selected independently from oxygen, sulfur and nitrogen, or, a bicyclic ring or a bicyclic ring with optional (C_1-C_3) bridge

optionally linked through (C_1-C_3)alkyl, said bicyclic ring or bridged bicyclic ring optionally having one to four heteroatoms selected independently from nitrogen, sulfur and oxygen wherein said (C_1-C_{10})alkyl, (C_1-C_{10})alkoxy, (C_3-C_{10})cycloalkoxy or R^4 ring(s) is optionally mono-, di- or tri-substituted independently with halo, (C_1-C_3)alkyl, trifluoromethyl, nitro, cyano, (C_3-C_5)cycloalkyl, hydroxy or (C_1-C_3)alkoxy, and

R^5 is H, (C_1-C_{10})alkyl or (C_1-C_{10})cycloalkyl; or R^4 and R^5 taken together with the nitrogen to which they are attached form a fully saturated or partially unsaturated four to nine membered ring, said ring optionally bridged, optionally having one to three additional heteroatoms selected independently from oxygen, sulfur and nitrogen, said ring optionally mono- or di-substituted independently with oxo, hydroxy, (C_1-C_6)alkoxy, (C_1-C_8)alkyl, amino, mono-N- or di-N,N-(C_1-C_4)alkylaminocarbonyl, mono-N- or di-N,N-(C_3-C_5)cycloalkyl- aminocarbonyl, N-(C_1-C_4)alkyl-N-(C_3-C_5)cycloalkylaminocarbonyl, mono-N- or di-N,N-(C_1-C_4)alkylamino, mono-N- or di-N,N-(C_3-C_5)cycloalkylamino, N-(C_1-C_4)alkyl-N-(C_3-C_5)cycloalkylamino, formylamino, (C_1-C_4)alkylcarbonylamino, (C_3-C_5)cycloalkylcarbonylamino, (C_1-C_4)alkoxycarbonylamino, N-(C_1-C_4)alkoxycarbonyl-N-(C_1-C_4)alkylamino, (C_1-C_4)sulfamoyl, (C_1-C_4)alkylsulfonylamino, (C_3-C_5)cycloalkylsulfonylamino or a partially saturated, fully saturated or fully unsaturated five to eight membered ring, optionally linked through (C_1-C_3)alkyl, optionally having one to three heteroatoms selected independently from oxygen, sulfur and nitrogen, or a bicyclic ring consisting of two fused partially saturated, fully saturated or fully unsaturated three to six membered rings, taken independently, optionally linked through (C_1-C_3)alkyl, optionally having one to four heteroatoms selected independently from nitrogen, sulfur and oxygen, optionally mono- or di-substituted with halo, trifluoromethyl, trifluoromethoxy,

(C_1-C_3)alkyl or (C_1-C_3)alkoxy;

a prodrug thereof or a pharmaceutical acceptable salt, hydrate or solvate of said compound or said prodrug;

provided that A is not -$(CH_2)_1$-, when R^{B1} is –D-G, R^{B4} is halo, trifluoromethyl, cyano, (C_1-C_3) alkyl, (C_1-C_3) alkyloxy, ethenyl or ethynyl, and R^{B2}, R^{B3} and R^{B5} are hydrogen.

31. (Currently Amended): The compound of Claim 30 wherein

X is oxy;

Y is N;

Z is H or Cl;

R^1 is (C_1-C_6)alkylcarbamoyl;

R^2 is H;

A is –$(CH_2)_n$-, where n is 1 or 2, or cyclopropyl; and

B is substituted or unsubstituted heteroaryl, naphthyl, -CH(aryl)$_2$, or



where R^{B1} is hydrogen, (C_1-C_4)alkyl, halo, hydroxy, thio, amino, (C_1-C_6)alkyloxy, (C_1-C_6)alkylthio, (C_1-C_6)alkylamino or -D-G,

R^{B2} is hydrogen, (C_1-C_4)alkyl, halo, hydroxy, thio, amino, (C_1-C_6)alkyloxy, (C_1-C_6)alkylthio, (C_1-C_6)alkylamino or ~~and~~ -D-G,

R^{B3} is hydrogen, (C_1-C_4)alkyl, halo, hydroxy, thio, amino, (C_1-C_6)alkyloxy, (C_1-C_6)alkylthio, (C_1-C_6)alkylamino or ~~and~~ -D-G,

R^{B4} is (C_1-C_4)alkyl, halo, hydroxy, thio, amino, (C_1-C_6)alkyloxy, (C_1-C_6)alkylthio, (C_1-C_6)alkylamino or ~~and~~ -D-G,

R^{B5} is hydrogen, (C_1-C_4)alkyl, halo, hydroxy, thio, amino, (C_1-C_6)alkyloxy, (C_1-C_6)alkylthio, (C_1-C_6)alkylamino or ~~and~~ -D-G,

D is oxy, thio, (C_1-C_6)alkyloxy or (C_1-C_6)alkylthio, and

G is phenyl, pyridyl, pyrimidinyl, pyrazinyl, thiazolyl, oxazolyl, isoxazolyl, pyridinazinyl, tetrazolyl, isothiazolyl, thiophenyl, furanyl, 1,2,4-oxadiazolyl, 1,2,4-thiadiazolyl, pyrazolyl, pyrrolyl, indolyl, naphthalenyl, quinolinyl, isoquinolinyl, benzo[b]furanyl, benzo[b]thiophenyl, benzothiazolyl, tetrahydrofuranyl, pyrrolidinyl, piperidinyl, tetrahydropyranyl, morpholinyl wherein said G is optionally mono-, di- or tri-substituted independently with halo, (C_1-C_3)alkyl or (C_1-C_3)alkoxy;

a prodrug thereof, or a pharmaceutically acceptable salt, hydrate or solvate of said compound or said prodrug.

32. (Previously Presented): The compound of Claim 31 wherein B is



where R^{B1} is $(C_1\text{-}C_4)$alkyl, halo, hydroxy, $(C_1\text{-}C_6)$alkyloxy or -D-G,

R^{B2} is hydrogen, $(C_1\text{-}C_4)$alkyl, halo, hydroxy, $(C_1\text{-}C_6)$alkyloxy or -D-G,

R^{B3} is hydrogen, $(C_1\text{-}C_4)$alkyl, halo, hydroxy, $(C_1\text{-}C_6)$alkyloxy or -D-G,

R^{B4} is $(C_1\text{-}C_4)$alkyl, halo, hydroxy, $(C_1\text{-}C_6)$alkyloxy or -D-G,

R^{B5} is hydrogen, $(C_1\text{-}C_4)$alkyl, halo, hydroxy, $(C_1\text{-}C_6)$alkyloxy or -D-G,

D is $(C_1\text{-}C_6)$alkoxy and

G is phenyl, pyridyl, thiazolyl, oxazolyl, isoxazolyl, isothiazolyl, furanyl, 1,2,4-oxadiazolyl, 1,2,4-thiadiazolyl, pyrazolyl, pyrrolyl, or morpholinyl wherein said G is optionally mono-, di- or tri-substituted independently with halo, $(C_1\text{-}C_3)$alkyl, trifluoromethoxy or $(C_1\text{-}C_3)$alkoxy;

a prodrug thereof, or a pharmaceutically acceptable salt, hydrate or solvate of said compound or said prodrug.

33. (New) A method of reducing tissue damage resulting from ischemia or hypoxia comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound, a prodrug thereof, or pharmaceutically acceptable salt, solvate, or hydrate of said compound or said prodrug according to Claim 1, 24, 27 or 30.

34. (New) A pharmaceutical composition which comprises a therapeutically effective amount of a compound, a prodrug thereof, or pharmaceutically acceptable salt, solvate, or hydrate of said compound or said prodrug according to Claim 1, 24, 27 or 30, and a pharmaceutically acceptable carrier, vehicle or diluent.

35. (New) A pharmaceutical kit comprising

a. a dosage form adapted for intravenous or intramuscular injection comprising a compound, a prodrug thereof, or pharmaceutically acceptable salt, solvate, or hydrate of said compound or said prodrug according to Claim 1, 24, 27 or 30; and

b. instructions describing a method of using the dosage form to reduce tissue damage resulting from ischemia or hypoxia.